Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5419]

ASCO 2021: Renal cancer roundup

Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA

ASCO 2021: Renal cancer roundup ( Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA )

Olaparib improves disease-free survival in high-risk early-stage HER2-negative...

Prof Andrew Tutt - Institute of Cancer Research, London, UK

Olaparib improves disease-free survival in high-risk early-stage HER2-negative breast cancer with BRCA 1/2 mutations ( Prof Andrew Tutt - Institute of Cancer Research, London, UK )

KEYNOTE-564: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

KEYNOTE-564: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first...

Dr Evan Jacob Lipson - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center...

RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma ( Dr Evan Jacob Lipson - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA )

European Cancer Organisation - Time to Act

Dr Mirjam Crul - Amsterdam University Medical Center, Amsterdam, Netherlands

European Cancer Organisation - Time to Act ( Dr Mirjam Crul - Amsterdam University Medical Center, Amsterdam, Netherlands )

European Cancer Organisation: Time To Act

Professor Mark Lawler - Queens University Belfast, Belfast, UK

European Cancer Organisation: Time To Act ( Professor Mark Lawler - Queens University Belfast, Belfast, UK )

Special Issue: Women’s cancer care in fragile, conflict-impacted ecosystems

Special issue authors and funders

Special Issue: Women’s cancer care in fragile, conflict-impacted ecosystems ( Special issue authors and funders )

PIPSeN trial: Olaparib maintenance vs placebo in platinum-sensitive non-small...

Dr Sophie Postel-Vinay - Gustave Roussey Cancer Center, Paris, France

PIPSeN trial: Olaparib maintenance vs placebo in platinum-sensitive non-small cell lung cancer ( Dr Sophie Postel-Vinay - Gustave Roussey Cancer Center, Paris, France )

Mechanisms of acquired resistance to KRAS G12C inhibition in cancer

Dr Mark Awad - Dana-Farber Cancer Institute, Boston, USA

Mechanisms of acquired resistance to KRAS G12C inhibition in cancer ( Dr Mark Awad - Dana-Farber Cancer Institute, Boston, USA )

OncoAlert and ecancer weekly roundup for April 19 - 25, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly roundup for April 19 - 25, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Understanding patient experience in Europe: The first Global Lung Cancer...

Vanessa Beattie - Lung Cancer Nursing UK, Solihull, England

Understanding patient experience in Europe: The first Global Lung Cancer Coalition Patient Experience Survey ( Vanessa Beattie - Lung Cancer Nursing UK, Solihull, England )

CONVERT trial: Patterns of relapse following thoracic radiotherapy in patients...

Dr Robin Portner - The Christie NHS Foundation Trust, Manchester, UK

CONVERT trial: Patterns of relapse following thoracic radiotherapy in patients with limited-stage SCLC ( Dr Robin Portner - The Christie NHS Foundation Trust, Manchester, UK )

More from ecancer